Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers  by Bona, Gianni et al.
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Background:  MenACWY-CRM  (Menveo®; GlaxoSmithKline)  and  MenACWY-TT  (Nimenrix®;  Pﬁzer)  are
two meningococcal  vaccines  licensed  in the  European  Union  for use  in both  children  and  adults.  While
both  vaccines  target  meningococcal  serogroups  A, C,  W  and  Y, immunogenicity  and  reactogenicity  of these
quadrivalent  meningococcal  conjugate  vaccines  may  differ due  to differences  in formulation  processes
and  chemical  structure.  Yet  data  on the  comparability  of  these  two vaccines  are  limited.
Methods:  The  reactogenicity  and  immunogenicity  of  one  dose  of  either  MenACWY-CRM  or  MenACWY-
TT  were  evaluated  in  healthy  toddlers  aged  12–15  months.  Immunogenicity  was  assessed  using serum
bactericidal  antibody  assays  (SBA)  with  human  (hSBA)  and  rabbit  (rSBA)  complement.
Results:  A  total of  202  children  aged  12–15  months  were  enrolled  to receive  one  dose  of MenACWY-CRM
or  MenACWY-TT.  Similar  numbers  of subjects  reported  solicited  reactions  within  7 days  following  either
vaccination.  Tenderness  at the  injection  site  was  the  most  common  local  reaction.  Systemic  reactions
reported  were  similar  for  both  vaccines  and mostly  mild to  moderate  in  severity:  irritability,  sleepiness
and  change  in  eating  habits  were  most  commonly  reported.  Immunogenicity  at  1 month  post-vaccination
was  generally  comparable  for both  vaccines  across  serogroups.  At  6 months  post-vaccination  antibody
persistence  against  serogroups  C,  W,  and Y was  substantial  for  both  vaccines,  as measured  by  both  assay
methodologies.  For  serogroup  A,  hSBA  titers  declined  in  both  groups,  while  rSBA  titers  remained  high.
Conclusion:  Despite  differences  in composition,  the  MenACWY-CRM  and  MenACWY-TT  vaccines  have
comparable  reactogenicity  and immunogenicity  proﬁles.  Immediate  immune  responses  and  short-term
antibody  persistence  were  largely  similar  between  groups.  Both  vaccines  were  well-tolerated  and  no
safety  concerns  were  identiﬁed.
© 2016  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Introduction
Neisseria meningitidis is a leading cause of bacterial meningitis
nd sepsis worldwide, particularly in young children under 5 years
f age. Invasive disease caused by this bacterium is often severe,
evelops rapidly and is associated with high rates of morbidity and
ortality, even with early antibiotic treatment [1].
∗ Corresponding author.
E-mail address: smolenov@gmail.com (I. Smolenov).
ttp://dx.doi.org/10.1016/j.vaccine.2016.05.009
264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
To date, meningococcal serogroups A, B, C, W,  and Y have been
identiﬁed as responsible for the majority of invasive meningococcal
disease (IMD) cases worldwide, and several quadrivalent conjugate
meningococcal vaccines offering protection against serogroups A,
C, W,  and Y are widely available. In the European Union (EU), there
are two  licensed quadrivalent conjugate meningococcal vaccines:
MenACWY-CRM (Menveo®; GlaxoSmithKline) and MenACWY-TT
(Nimenrix®; Pﬁzer). MenACWY-CRM is an oligosaccharide diph-
theria CRM197 conjugate vaccine containing bacterial capsular
oligosaccharides for serogroups A, C, W,  and Y conjugated to a
protein carrier cross reactive material 197 (CRM197). Oligosaccha-
rides are prepared from puriﬁed polysaccharides by hydrolysis,
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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izing and reductive amination, and then covalently linked to the
RM197 [2]. MenACWY-TT is a tetravalent meningococcal polysac-
haride conjugated vaccine consisting of N. meningitidis capsular
olysaccharides A, C, W,  and Y each coupled to tetanus toxoid (TT)
s the carrier protein. The serogroup A and C polysaccharides are
onjugated with an adipic dihydrazide (AH) spacer and indirectly
onjugated to the TT, whereas the W and Y polysaccharides are con-
ugated directly to the TT. MenACWY-CRM was licensed in 2010 and
s currently approved for individuals over 2 years of age in the EU
nd from 2 months to 55 years of age in the USA. MenACWY-TT was
icensed in 2012 and is currently approved in the EU for individuals
ver 12 months of age.
Both MenACWY-CRM and MenACWY-TT protect against IMD
aused by serogroups A, C, W,  and Y. However, due to differ-
nces in polysaccharide chain length, conjugation chemistry for
rotein−polysaccharide coupling, and carrier protein, it is possi-
le that the reactogenicity and immunogenicity of these vaccines
iffer. To date, only a single study has directly compared these
accines when administered as a booster dose in adolescents previ-
usly vaccinated with meningococcal C conjugate vaccines [3]. Both
accines induced bactericidal antibodies to levels associated with
rotection in comparable proportions of subjects. Both vaccines
ere also well-tolerated and no safety concerns were identiﬁed.
owever, a similar evaluation of the two vaccines has not been
erformed in young children or after primary vaccination. Indirect
omparisons across studies are inappropriate due to differences
n serological assays used in different laboratories and in methods
sed to assess reactogenicity.
A serum bactericidal assay using human complement (hSBA)
s commonly used to measure vaccine immunogenicity against N.
eningitidis. It is based on the observation that an hSBA titer ≥4 cor-
elates with protection against IMD, as described by Goldschneider
nd colleagues [2,3]. During the development of MenACWY-CRM,
 more conservative hSBA titer level (≥8) was selected in order
o avoid overestimation of protection [4]. However, despite the
cceptance of hSBA data as the basis for vaccine licensure, this
ssay is difﬁcult to standardize across laboratories due to the
ature of the reagents. For example, different sources of human
omplement may  yield different results, as can the selection and
anagement of test strains. Ultimately, while substantial efforts
ave been made to standardize the hSBA assay and its compo-
ents [5,6], results from different laboratories cannot be readily
ompared.
The bactericidal assay using complement derived from baby rab-
it serum (rSBA) is a widely accepted alternative to the hSBA, in
hich an rSBA titer of ≥128 is approximately equivalent to an hSBA
iter of ≥4 [7]. However, while rSBA titers of ≥128 reliably predict
rotection, more recent data have suggested that this threshold
ay  be unnecessarily stringent and that an rSBA titer of ≥8 is suf-
cient [8,9].
In the present study, we directly assessed the tolerability and
mmunogenicity of a single dose of MenACWY-CRM or MenACWY-
T in 12–15 month old toddlers using uniform safety assessments
nd serological assays (hSBA and rSBA).
. Methods
This Phase II, randomized, controlled, observer-blind, multicen-
er study was conducted in four centers in Italy between November
013 and October 2014. The primary objective was  to assess the
eactogenicity of single doses of MenACWY-CRM or Men  ACWY-
T vaccines in healthy toddlers (NCT01994629). The study was
esigned and conducted in accordance with the ICH Harmonized
ripartite Guidelines for Good Clinical Practice, applicable local reg-
lations, and the Declaration of Helsinki. (2016) 3363–3370
2.1. Subjects
Children aged 12–15 months in good health, whose par-
ent(s)/legal guardian(s) had provided written informed consent,
and who were expected to be available for all study visits were
included. Exclusion criteria included: serious, acute, or chronic ill-
ness; a history of allergy to any vaccine component; previous or
suspected disease caused by N. meningitidis; previous immuniza-
tion with any meningococcal vaccine; planned or actual receipt of
any vaccines within 14 days prior to or 30 days after administration
of the study vaccine (with the exception of the inﬂuenza vaccine).
Subjects were enrolled and randomized according to a 1:1 ratio
into either the ACWY-CRM or the ACWY-TT group, each to receive
one dose of study vaccine on Day 1 (see Fig. 1 for study design).
Randomization was  performed using a centralized randomiza-
tion system (interactive response technology [IRT]). Blood samples
were collected from all toddlers on Days 1 (prevaccination), 29 (1
month) and 180 (6 months).
2.2. Vaccines
The MenACWY-CRM vaccine was reconstituted immediately
prior to injection by adding a vial of the liquid MenCWY component
to a vial of the lyophilized MenA component. Each reconstituted
dose of MenACWY-CRM contained 10 g MenA and 5 g each of
MenC, MenW,  and MenY. The MenACWY-TT vaccine was recon-
stituted by adding the entire contents of the preﬁlled syringe of
solvent to the vial containing the powdered components. Each
reconstituted dose contained 5 g each of MenA, MenC, MenW,
and MenY. Both vaccines were administered as a 0.5 mL dose by
intramuscular injection into the anterolateral right thigh.
2.3. Safety assessments
Reactogenicity was measured as percentages of subjects repor-
ting at least one severe solicited adverse event (AE) within 7 days
post-vaccination. Solicited AEs included tenderness, erythema,
induration, irritability, sleepiness, change in eating habits, vomi-
ting, diarrhea, and fever (body temperature ≥38 ◦C). Solicited AEs
were collected using diary cards.
Secondary safety assessments included solicited local and sys-
temic AEs, of any severity, within 7 days post-vaccination, any
unsolicited AEs through Day 29, and any medically attended AEs,
serious AEs (SAEs) or AEs leading to premature withdrawal during
the entire study.
2.4. Immunogenicity assessments
The immunogenicity objectives were to assess the immuno-
genicity of one dose of either MenACWY-CRM or MenACWY-TT
on Day 29, and to assess the persistence of immune responses
on Day 180. Immune responses against serogroups A, C, W,  and
Y were measured by serum bactericidal assay (SBA) as described
previously [10] using human and rabbit complement (hSBA and
rSBA). Results are expressed as: (1) percentages of subjects with
hSBA/rSBA titers ≥8; (2) percentages of subjects with rSBA titers
≥128; (3) percentages of subjects with hSBA seroresponse (an
increase in hSBA titers from <4 pre-vaccination to ≥8 post-
vaccination, or an at least 4-fold increase in hSBA titers for
subjects with pre-vaccination titers ≥4); (4) percentages of subjects
with a 4-fold increase in rSBA titers; (5) hSBA/rSBA geomet-
ric mean titers (GMTs); and (6) geometric mean ratios (GMRs;
post-vaccination/baseline).hSBA testing was  performed at Clinical
Laboratory Sciences, Novartis Vaccines and Diagnostics (now Glax-
oSmithKline), Marburg. The qualiﬁcation procedures for human
complement were performed according to the laboratory standard
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Enrolled  subjects (N =202) 
MenACWY- CRM group 
n=100
MenACWY -TT  group 
n=102
DAY 1 
Receive d AC WY-CR M va cci nat ion 
(IM) 
Blood  sample  (5  ml) 
n=99
Received ACWY-TT vaccination  (IM) 
Blood sample (5 ml) 
n=102
Solicited/Unsolicited AEs/body temperature monitored for 30 mins post-vaccination 
Solicit ed AE s reco rded for 7 da ys pos t-vac cinati on 
Unsolicited AEs recorded for 29  days post-vaccination 
Medically  atten ded/Serious  AEs  collecte d until  Day 18 0
DAY 29 
Blood  sample  (5  ml) 
n=99
Blood  sample  (5  ml) 
n=99
DAY 180  Blood  sample  (5  ml)    Blood  sample  (5  ml) 
99 comp lete d pr otocol 
1 withdra wal on Da y 1 
99 comp lete d pr otocol 
3 lost to foll ow up on Days 9, 89 and 91 
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and 101 in the ACWY-TT group) were included in safety evalua-
tions; one subject was  excluded due to lack of post-vaccination
safety data.
Table 1
Demographics and baseline characteristics of subjects.
MenACWY-CRM MenACWY-TT Total
N  = 100 N = 102 N = 202
Age in months(mean ± SD) 12.8 ± 1.0 12.7 ± 0.9 12.7 ± 0.9
Sex, n (%)
Female 48 (48) 46 (45.1) 94 (46.5)
Male 52 (52) 56 (54.9) 108 (53.3)
Ethnic origin, n (%)
Asian 0 1 (1) 1 (0.5)
Black or African American 0 2 (2) 2 (1)Fig. 1. S
peration procedures. A single lot of human complement was  used
or testing of all clinical samples against each vaccine serogroup.
SBA testing was performed at Public Health England (PHE, UK).
.5. Statistical methods
For the primary endpoint, two-sided 95% conﬁdence intervals
CIs) for the difference in percentages of subjects with severe
olicited AEs between the groups (ACWY-CRM and ACWY-TT) were
omputed using the methodology of Miettinen and Nurminen [11].
ll other reactogenicity, immunogenicity and safety analyses were
escriptive; two-sided 95% CIs were calculated using the Clopper-
earson method. Safety analyses included all subjects who  received
t least one dose of vaccine and provided any safety data. Since <10%
f subjects were terminated from the study or reported protocol
eviations, the immunogenicity analysis was based on all subjects
ho received a study vaccine and provided an evaluable serum
ample at Day 180 (Full Analysis Set).
With 100 enrolled subjects per arm, the study has power of
0% to detect a 11% increase in proportion of subjects with severe
olicited AEs between the ACWY-CRM and the ACWY-TT group,
ssuming the rate of severe reactions in a reference group of 5%
nd alpha of 0.05.
. Results.1. Demographics
A total of 202 subjects were enrolled in this study, of which
01 subjects (99 in the ACWY-CRM group and 102 in thedesign.
ACWY-TT group) received the study vaccine (see Fig. 1). Demo-
graphic and baseline characteristics were balanced between the
groups (Table 1). The mean age of the subjects was 12.7 months
and the majority were Caucasian (95%). Nearly all subjects (99%
in the ACWY-CRM group and 97.1% in the ACWY-TT group) com-
pleted the study. Four subjects withdrew prematurely; of these, one
subject (ACWY-CRM group) withdrew consent and three subjects
(ACWY-TT group) were lost to follow-up.
3.2. Safety
Of the 201 vaccinated subjects, 200 (99 in the ACWY-CRM groupCaucasian 96 (96) 96 (94.1) 192 (95)
Other 4 (4) 3 (2.9) 7 (3.5)
Weight in Kg (mean ± SD) 10 ± 1.1 10 ± 1.3 10 ± 1.2
Height in cm (mean ± SD) 77 ± 3.2 76.5 ± 3.6 76.8 ± 3.4
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.2.1. Solicited reactions
Two hundred subjects were evaluated for solicited AEs reported
ithin 7 days post-vaccination. The frequencies of severe solicited
Es reported were comparable between groups: four (4%) subjects
n the ACWY-CRM group and two (2%) subjects in the ACWY-TT
roup, an intergroup difference of 2% (95% CI -3.4%, 8.2%). Simi-
ar numbers of subjects reported at least one solicited AE within 7
ays in both the ACWY-CRM (67.7%) and ACWY-TT (63.4%) groups
Table 2). A greater number of subjects in the ACWY-CRM group
34.3%) reported local solicited AEs than in the ACWY-TT group
28.7%). Tenderness at the injection site was the most common
ocal solicited AE, reported by 29.9% of subjects in ACWY-CRM
roup and 26% of subjects in the ACWY-TT group. The incidence of
rythema (ACWY-CRM: 4.1%; ACWY-TT: 2%) or induration (ACWY-
RM: 6.2%; ACWY-TT: 4%) was similar in both groups. There was
nly one severe local reaction (induration) reported by one subject
n the ACWY-CRM group.
Systemic solicited AEs were reported by similar numbers of
ubjects in both groups (56.6% and 56.4% in the ACWY-CRM and
CWY-TT groups, respectively). Irritability, sleepiness, and change
n eating habits were most commonly reported solicited systemic
Es (Table 2). A total of three subjects in the ACWY-CRM group
eported eight severe systemic AEs, while two  subjects in the
CWY-TT group reported four severe systemic AEs. Fever (temper-
ture ≥ 38 ◦C) was reported by 14.1% of subjects in the ACWY-CRM
roup and by 13% of subjects in the ACWY-TT group. There were
o instances of severe fever (≥ 40 ◦C). Most reported solicited AEs
ere mild to moderate and resolved by Day 7.
able 2
umber of subjects (%) with solicited and unsolicited adverse events post- vaccina-
ion with MenACWY-TT and MenACWY-CRM.
MenACWY-CRM
(N = 99)
MenACWY-TT
(N = 101)
Any Solicited AEs (Days 1−7) 67 (67.7%) 64 (63.4%)
Any  Severe AEs 4 (4%) 2 (2%)
Any  Local Solicited AEs 34 (34.3%) 29 (28.7%)
Tenderness
Any  29 (29.9%) 26 (26%)
Severe 0 0
Erythema
Any  4 (4.1%) 2 (2%)
>50  mm 0 0
Induration
Any  6 (6.2%) 4 (4%)
>50  mm 1 (1%) 0
Any  Systemic Solicited AEs 56 (56.6%) 57 (56.4%)
Change in eating habits
Any 22 (22.9%) 26 (26%)
Severe 3 (3.1%) 1 (1%)
Sleepiness
Any  23 (24%) 26 (26.5%)
Severe 2 (2.1%) 0
Irritability
Any  30 (31.3%) 39 (39.4%)
Severe 3 (3.1%) 1 (1%)
Vomiting
Any  6 (6.3%) 9 (9.1%)
Severe 0 1 (1%)
Diarrhea
Any  17 (17.7%) 18 (18.2%)
Severe 0 1 (1%)
Fever (≥38 ◦C)
Any 14 (14.1%) 13 (13%)
Severe (≥40 ◦C) 0 0
Any  Unsolicited AEs 73 (73.7%) 71 (70.3%)
Possibly/probably related AEs 12 (12.1%) 14 (13.9%)
Serious AEs (Through Day 180) 8 (8.1%) 3 (3%)
Possibly/probably related SAEs 0 0
Medically attended AEs 73 (73.7%) 68 (67.3%)
Death 0 0 (2016) 3363–3370
3.2.2. Unsolicited AEs
Unsolicited AEs were reported by 73.7% of subjects in the
ACWY-CRM group and by 70.3% of subjects in the ACWY-TT group
(Table 2). Percentages of possibly related unsolicited AEs and medi-
cally attended AEs were similar between groups. Eleven SAEs (eight
in the ACWY-CRM group and three in the ACWY-TT group) were
reported: ﬁve infectious illnesses (all between Days 14 and 170
post-vaccination), two injuries (Days 22 and 65), two febrile con-
vulsions (Day 2 [concurrent with infectious illness] and Day 38),
one respiratory disorder (Day 109) and one skin rash (Day 48);
none were considered related to the study vaccines (Table 2). Over-
all, the MenACWY-CRM and MenACWY-TT vaccines had similar
reactogenicity proﬁles in healthy toddlers.
3.3. Immunogenicity
At baseline, only 0–6% of subjects had hSBA titers ≥ 8 against
serotypes A, C, W,  or Y (Fig. 2). 1 month post-vaccination (Day 29),
hSBA responses to both MenACWY-CRM and MenACWY-TT were
comparable, albeit serogroup speciﬁc. Namely, the majority of sub-
jects in the ACWY-CRM and ACWY-TT groups had hSBA titers ≥ 8
against serogroup A (90% and 88%, respectively) and C (96% and 86%,
respectively), while the proportions of subjects with hSBA titers ≥
8 against serogroups W and Y were lower (62–72% and 41–56%,
respectively).
This trend was  also seen across other immunogenicity end-
points. At Day 29, hSBA GMTs against serogroups A and C were ∼9-
to 18-fold higher than baseline across vaccine groups, but only ∼3-
to ∼6-fold higher against serogroups W and Y (Table 3). Likewise,
greater proportions of subjects achieved seroresponses against
serogroups A (87–88%) and C (84–95%) than against serogroups W
(54–73%) and Y (39–54%).
Immune responses, as measured by rSBA, were generally higher
than those measured by hSBA.
In both vaccine groups, rSBA titers ≥ 8 and ≥ 128 on Day 29
were observed in all (100%) subjects against serogroup A, and in
the majority of subjects against serogroups C, W and Y (89–97% had
rSBA titers ≥ 8 and 65–90% had rSBA titers ≥ 128; Fig. 3). Serogroup-
speciﬁc increases in rSBA GMTs on Day 29 (Table 3) were likewise
similar between the two  vaccine groups for serogroups C, W,  and Y,
with increases in rSBA GMTs against serogroup C being lower (76-
to 79-fold increase over baseline) than those against serogroups Y
(240- to 285-fold) and W (380- to 482-fold). For serogroup A, rSBA
GMTs increased more in the ACWY-CRM group (854-fold higher
than baseline) than in the ACWY-TT group (228-fold higher than
baseline). A 4-fold increase in rSBA titers over baseline was also
observed for all serogroups in most subjects (65–100%) across both
vaccine groups.
3.4. Antibody persistence
By Day 180, the proportion of subjects with hSBA titers ≥ 8
against serogroup A declined in both groups but to a greater degree
in the ACWY-TT group (ACWY-TT: 30% had hSBA titers ≥ 8; ACWY-
CRM: 65% had hSBA titers ≥ 8).
Against serogroup C, the proportion of subjects with hSBA titers
≥ 8 remained constant, with a trend toward increased antibody
persistence in the ACWY-TT group. Unexpectedly, the proportion
of subjects with hSBA titers ≥ 8 against serogroups W and Y on Day
180 increased above those on Day 29 with titers in the ACWY-TT
group being higher than in the ACWY-CRM group (Fig. 2). Simi-
lar patterns were observed for hSBA GMTs on Day  180 (6 months;
Table 3).
In contrast to the decrease in hSBA titers against serogroup A
on Day 180, the proportion of subjects with rSBA titers ≥ 8 or ≥
128 against serogroup A on Day 180 remained relatively constant
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Fig. 2. Percentages of subjects (95% CI) with hSBA titers ≥ 8, against serogroups A, C, W and Y at baseline, 1 month and 6 months post-vaccination with MenACWY-TT or
MenACWY-CRM.
Table 3
hSBA and rSBA GMTs and GMRs (95% CI) against N. meningitidis serogroups A, C, W and Y at baseline, 1 month and 6 months post-vaccination with MenACWY-TT or
MenACWY-CRM.
hSBA rSBA
Serogroup MenACWY-CRM MenACWY-TT MenACWY-CRM MenACWY-TT
A GMT  Baseline 2.2 (2.0–2.4) 2.0(1.9–2.2) 8.6 (3.9–19) 15 (6.8–35)
(N = 95) (N = 92) (N = 60) (N = 61)
1  Month 41 (31–55) 30 (22–39) 5275 (3742–7437) 2884 (2061–4035)
(N  = 89) (N = 93) (N = 57) (N = 56)
6  Months 13 (9.5–18) 4.7 (3.4–6.4) 2815 (1741–4550) 950 (592–1523)
(N  = 97) (N = 96) (N = 74) (N = 75)
GMR  1 Month/Baseline 18 (13–25) 14 (11–19) 854 (364–2004) 228 (92–567)
(N  = 87) (N = 90) (N = 50) (N = 46)
6  Months/Baseline 5.9 (4.3–8.2) 2.3 (1.6–3.1) 296 (123–715) 59 (24–146)
(N = 95) (N = 92) (N = 60) (N = 61)
C  GMT  Baseline 2.4 (2.2–2.6) 2.27 (2.1–2.5) 2.5 (2.0–3.1) 2.1 (1.7–2.6)
(N  = 94) (N = 92) (N = 64) (N = 63)
1  Month 30 (23–38) 22 (17–28) 202 (130–314) 160 (104–248)
(N  = 91) (N = 92) (N = 61) (N = 57)
6  Months 24 (18–30) 41 (32–53) 20 (12–33) 22 (13–36)
(N = 96) (N = 95) (N = 77) (N = 76)
GMR  1 Month/Baseline 12 (9.6–16) 9.4 (7.3–12)( 79 (46–133) 76 (43–133)
(N = 89) N = 90) (N = 54) (N = 48)
6  Months/Baseline 9.9 (7.6–13) 18 (13–23) 6.9 (3.9–12) 8.7 (4.9–16)
(N  = 94) (N = 92) (N = 64) (N = 63)
W  GMT  Baseline 2.4 (2.1–2.7) 2.3 (2.0–2.6) 2.6 (2.0–3.2) 2.0 (1.6–2.6)
(N = 83) (N = 81) (N = 58) (N = 58)
1  Month 8.6 (6.2–12) 15 (10–20) 1478 (768–2846) 974 (509–1864)
(N  = 74) (N = 78) (N = 55) (N = 50)
6  Months 21 (17–27) 56 (45–70) 91 (46–182) 142 (72–282)
(N  = 88) (N = 89) (N = 73) (N = 70)
GMR  1 Month/Baseline 3.5 (2.4–5.0) 6.5 (4.5–9.5) 482 (213–1093) 380 (157–916)
(N  = 71) (N = 71) (N = 48) (N = 42)
6  Months/Baseline 8.6 (6.72–11) 24 (19–31) 24 (11–54) 54 (24–122)
(N = 83) (N = 81) (N = 58) (N = 58)
Y  GMT  Baseline 2.3 (2.1–2.6) 2.3 (2.0–2.5) 3.0 (1.9–5.0) 2.9 (1.7–4.8)
(N  = 88) (N = 87) (N = 61) (N = 59)
1  Month 5.8 (4.2–8.0) 8.1 (5.9–11) 762 (367–1583) 566 (273–1173)
(N  = 81) (N = 87) (N = 54) (N = 50)
6  Months 16 (12–21) 26 (20–34) 248 (124–495) 140 (70–278)
(N  = 92) (N = 95) (N = 74) (N = 71)
GMR  1 Month/Baseline 2.7 (1.9–3.8)( 3.8 (2.7–5.3) 240 (103–559) 285 (114–714)
(N  = 78) (N = 81) (N = 48) (N = 42)
6  Months/Baseline 6.8 (5.1–9.0) 11 (8.7–15) 88 (39–196) 55 (24–125)
(N = 88) (N = 87) (N = 61) (N = 59)
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≥ig. 3. Percentages of subjects (95% CI) with rSBA titers ≥ 8, against serogroups A
enACWY-CRM.
93–100% and 91–100% had rSBA titers ≥ 8 and ≥ 128, respectively).
or serogroups C, W,  and Y, rSBA titers decreased between Days 29
nd 180 in both groups. Despite the decreases in rSBA titers by
ay 180, rSBA titers remained substantial in both vaccine groups
64–71%, 71–87%, 80–82% subjects had rSBA ≥ 8 for serogroups
, W,  and Y, respectively, and 25–33%, and 62–66%, 62–73% sub-
ects had rSBA ≥ 128). These serogroup-speciﬁc patterns were also
bserved for rSBA GMTs, which declined for all serogroups to a
omparable extent in both vaccine groups (Table 3).
. Discussion
This Phase 2 study veriﬁed that a single dose of either the
enACWY-CRM or MenACWY-TT vaccine elicit comparable reac-
ogenicity and immunogenicity responses in healthy toddlers.
In an earlier report, Ishola and colleagues [3] compared booster
oses of MenACWY-CRM and MenACWY-TT in adolescents pre-
iously vaccinated with MenC vaccines. In their study, overall
eactogenicity to both vaccines was similar, and severe solicited
eactions were “generally rare”, although details regarding solicited
r unsolicited AEs following the vaccinations were not provided.
n the present study, severe solicited AEs were likewise reported
y only a few subjects (ACWY-CRM: 4/99; ACWY-TT: 2/100), and
ocal and systemic solicited AEs were comparable between the
roups. Moreover, the incidence of local and systemic solicited
Es is consistent with previous studies of MenACWY-CRM [12–14]
nd MenACWY-TT [15–18] in toddlers. However, in some stud-
es, the reported incidence of erythema following MenACWY-TT or
enACWY-CRM vaccination is higher than reported here [13–19].
Serum bactericidal assay with human complement was selected
s the primary assay for this study since hSBA titer ≥4 is a well-
ccepted surrogate of protection against meningococcal disease
4,20]. However, hSBA results are highly dependent on the human
omplement used for the assay. In the present study, rigorous com-
lement qualiﬁcation procedures were routinely implemented to
uarantee comparability of the results over time within the labora-
ory, and serum from a single qualiﬁed donor was used as a source
f complement for testing all the clinical samples for each vaccine
erogroup.
One month post-vaccination (Day 29), a robust immune
esponse (indicated by the percentage of subjects with hSBA titers
 8 and hSBA GMTs) was seen in both vaccine groups against all and Y at baseline, 1 month and 6 months post-vaccination with MenACWY-TT or
serogroups, particularly A and C. Previous reports of immunogenic-
ity one month after a single dose of MenACWY-CRM [14,21] or
MenACWY-TT [15,22] in toddlers have also demonstrated higher
hSBA responses to serogroups A and C than for serogroups W and
Y. In general, while overall immunogenicity against MenACWY-
CRM and MenACWY-TT in the present and previous studies is
comparable, there is substantial variability across studies in terms
of hSBA immune response to each serogroup [14,22,23]. Differ-
ences in immune responses in the current and previous studies
could reﬂect variations in study design, assay methodologies and
human complement qualiﬁcation procedures used by different
laboratories as well as different regional demographics or IMD
epidemiology.
With the exception of serogroup A, short-term persistence of
immune responses to all serogroups at 6 months post-vaccination
with MenACWY-CRM or MenACWY-TT was  substantial. hSBA titers
to serogroup A, however, declined in both vaccine groups, to a
greater extent in the ACWY-TT group. Consistent with the present
study, Baxter et al. [20] recently reported that hSBA titers to
serogroup A 1 year post single vaccination in adolescents with
MenACWY-TT were markedly lower than to serogroups C, W,  and
Y.
Interestingly, the percentages of subjects with hSBA titers ≥8
against serogroups W and Y were higher at 6 months than at 1
month post-vaccination. A similar increase in seropositivity rates
against these two  serogroups after a single dose vaccination in tod-
dlers was observed in previous studies with MenACWY-TT [15]
and MenACWY-CRM [NCT01345721]. This could reﬂect natural
exposure to circulating serogroups W and Y (or cross-reacting
pathogens) in this age group, or could indicate that the kinetics
of hSBA immune response after a single vaccination with conju-
gate meningococcal vaccines is serogroup-speciﬁc. Note that no
increase in hSBA titers was observed at approximately 6 months
after a two-dose vaccination with MenACWY-CRM in toddlers
(NCT01345721).
Serum bactericidal assay with rabbit complement was used as
a secondary assay in this study.
Standardized rabbit complement is commercially available for
use in rSBA assays and is known to be associated with less
inter-laboratory variability when compared with the hSBA assay.
However, although a strong correlation between rSBA and hSBA
assays has been consistently demonstrated for serogroup C, it has
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ot for serogroups A, W,  and Y [24]. Moreover, samples lacking
etectable hSBA activity were frequently positive by rSBA [24,25].
Both study vaccines induced robust rSBA responses at 1 month
fter a single dose, with a vast majority of subjects achieving rSBA
iter ≥ 8. A moderate and comparable decline in rSBA titers against
erogroups C, W,  and Y was observed at 6 months after vaccinaton
n both vaccine groups. This pattern of antibody decline was similar
o that previously described for MenACWY-TT [15] and MenACWY-
RM [26] vaccines.
The proportion of subjects with rSBA titers ≥ 8 against serogroup
 remained constant within 6 months after vaccination. This obser-
ation is in line with recent studies of MenAfriVac vaccine, which
emonstrated sustained antibody persistence for serogroup A (up
o 5 years post-vaccination) using the rSBA assay [27,28]. The per-
istence of rSBA titers in MenAfriVac studies corresponds, in turn,
ith sustained reduction in invasive meningococcal disease and
eduction of carriage in countries with high incidence of serogroup
 disease [20,29,30]. This may  indicate that rSBA might be more
ppropriate for monitoring antibody persistence and associated
rotection against IMD  caused by serogroup A. Expanded immuno-
ogic and epidemiologic surveillance is needed to improve the
nterpretation of differences between the immunoassays [31].
Overall, taking hSBA and rSBA results together, there were no
ppreciable differences in the immune responses between the
enACWY-CRM and MenACWY-TT groups 1 month after a sin-
le vaccination in toddlers, and no consistent difference in the
ersistence of antibody titers at 6 months. However, there are
everal limitations to consider: Firstly, the investigation was  not
ufﬁciently powered to perform statistical between-group com-
arisons. Secondly, this study included only four study sites from a
ingle country; results may  not be representative of other regions
ith different meningococcal disease epidemiology.
In conclusion, the reactogenicity and safety proﬁles of the
enACWY-CRM and MenACWY-TT vaccines were similar in
ealthy 12–15 month-old toddlers, with no safety concerns
dentiﬁed. Furthermore, single doses of MenACWY-CRM or
enACWY-TT-induced robust immune responses with limited dif-
erences between groups at 1 month (immunogenicity), and 6
onths (antibody persistence) post-vaccination.
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